Characterization of a respiratory syncytial virus L protein inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3867-3873

  Tiong Yip, Choi Lai ^a   Aschenbrenner, Lisa ^a   Johnson, Kenneth D ^a   McLaughlin, Robert E ^a   Fan, Jun ^a   Challa, SreeRupa ^a   Xiong, Hui ^a   Yu, Qin ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (2 FLUOROPHENYL)UREA; ANTIVIRUS AGENT; AZ 27; DIHYDROLIPOAMIDE DEHYDROGENASE; MESSENGER RNA; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; YM 53403; 6-(4-((BIPHENYL-2-YLCARBONYL) AMINO)BENZOYL)1-N-CYCLOPROPYL-5,6-DIHYDRO-4H-THIENO(3,2-D)(1)BENZAZEPINE-2-CARBOXAMIDE; AZ-27 COMPOUND; BENZAZEPINE DERIVATIVE; CYCLOPROPANE DERIVATIVE; NICOTINAMIDE; RNA DIRECTED RNA POLYMERASE; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BHK CELL LINE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEK293 CELL LINE; HEP 2 CELL LINE; MUMPS VIRUS; NEWCASTLE DISEASE PARAMYXOVIRUS; NIPAH VIRUS; NONHUMAN; PARAINFLUENZA VIRUS 2; PRIORITY JOURNAL; REPLICON; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA REPLICATION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS GENOME; VIRUS REPLICATION; VIRUS RESISTANCE; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MOLECULAR GENETICS; POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIROLOGY;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BENZAZEPINES; CELL LINE; CELL SURVIVAL; CYCLOPROPANES; DRUG RESISTANCE, VIRAL; HUMANS; MOLECULAR SEQUENCE DATA; NIACINAMIDE; POLYMERASE CHAIN REACTION; REPLICON; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RNA REPLICASE; VIRAL PROTEINS;

EID: 84903194455     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02540-14     Document Type: Article

References (19)

1. Collins PL, Fearns R, Graham BS. 2013. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr. Top. Microbiol. Immunol. 372:3-38. http://dx.doi.org/10.1007/978-3-642-38919-1-1.
2. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162:80-99. http://dx.doi.org/10.1016/j.virusres.2011.09.020.
3. Borchers AT, Chang C, Gershwin ME, Gershwin LJ. 2013. Respiratory syncytial virus - a comprehensive review. Clin. Rev. Allergy Immunol. 45:331-379. http://dx.doi.org/10.1007/s12016-013-8368-9.
4. Roymans D, Koul A. 2011. Treatment of respiratory syncytial virus infection: past, present and future. In Resch B (ed), Human respiratory syncytial virus infection. InTech, Rijeka, Croatia. http://dx.doi.org/10.5772/ 26528.
5. Lay MK, Gonzalez PA, Leon MA, Cespedes PF, Bueno SM, Riedel CA, Kalergis AM. 2013. Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response. Microbes Infect. 15:230-242. http://dx.doi.org/10.1016/j.micinf.2012.11.012.
6. Chapman J, Abbott E, Alber DG, Baxter RC, Bithell SK, Henderson EA, Carter MC, Chambers P, Chubb A, Cockerill GS, Collins PL, Dowdell VC, Keegan SJ, Kelsey RD, Lockyer MJ, Luongo C, Najarro P, Pickles RJ, Simmonds M, Taylor D, Tyms S, Wilson LJ, Powell KL. 2007. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. 51:3346-3353. http://dx.doi.org/10.1128/AAC.00211-07. (Pubitemid 350067550)
7. Morin B, Kranzusch PJ, Rahmeh AA, Whelan SP. 2013. The polymerase of negative-stranded RNA viruses. Curr. Opin. Virol. 3:103-110. http://dx.doi.org/10.1016/j.coviro.2013.03.008.
8. Dochow M, Krumm SA, Crowe JE, Jr, Moore ML, Plemper RK. 2012. Independent structural domains in paramyxovirus polymerase protein. J. Biol. Chem. 287:6878-6891. http://dx.doi.org/10.1074/jbc.M111.325258.
9. Tremaglio CZ, Noton SL, Deflube LR, Fearns R. 2013. Respiratory syncytial virus polymerase can initiate transcription from position 3 of the leader promoter. J. Virol. 87:3196-3207. http://dx.doi.org/10.1128/JVI.02862-12.
10. Gopinath M, Shaila MS. 2009. RNA triphosphatase and guanylyl transferase activities are associated with the RNA polymerase protein L of rinderpest virus. J. Gen. Virol. 90:1748-1756. http://dx.doi.org/10.1099/vir.0.010975-0.
11. Mason SW, Lawetz C, Gaudette Y, Do F, Scouten E, Lagace L, Simoneau B, Liuzzi M. 2004. Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. Nucleic Acids Res. 32:4758-4767. http://dx.doi.org/10.1093/nar/gkh809. (Pubitemid 39429680)
12. Liuzzi M, Mason SW, Cartier M, Lawetz C, McCollum RS, Dansereau N, Bolger G, Lapeyre N, Gaudette Y, Lagacé L, Massariol MJ, Dô F, Whitehead P, Lamarre L, Scouten E, Bordeleau J, Landry S, Rancourt J, Fazal G, Simoneau B. 2005. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J. Virol. 79:13105-13115. http://dx.doi.org/10.1128/JVI.79.20.13105-13115.2005. (Pubitemid 41433229)
13. Sudo K, Miyazaki Y, Kojima N, Kobayashi M, Suzuki H, Shintani M, Shimizu Y. 2005. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res. 65:125-131. http://dx.doi.org/10.1016/j. antiviral.2004.12.002. (Pubitemid 40222289)
14. Xiong H, Foulk M, Aschenbrenner L, Fan J, Tiong-Yip CL, Johnson KD, Moustakas D, Fleming PR, Brown DG, Zhang M, Ferguson D, Wu D, Yu Q. 2013. Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor. Bioorg. Med. Chem. Lett. 23:6789-6793. http://dx.doi.org/10.1016/j.bmcl.2013.10. 018.
15. Malykhina O, Yednak MA, Collins PL, Olivo PD, Peeples ME. 2011. A respiratory syncytial virus replicon that is noncytotoxic and capable of long-term foreign gene expression. J. Virol. 85:4792-4801. http://dx.doi.org/10. 1128/JVI.02399-10.
16. Tiong-Yip CL, Plant H, Sharpe P, Fan J, Rich K, Gorseth E, Yu Q. 2014. Development of a high-throughput replicon assay for the identification of respiratory syncytial virus inhibitors. Antiviral Res. 101:75-81. http://dx.doi.org/10.1016/j.antiviral.2013.11.003.
17. Zhu Q, Patel NK, McAuliffe JM, Zhu W, Wachter L, McCarthy MP, Suzich JA. 2012. Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. J. Infect. Dis. 205:635-638. http://dx.doi.org/10.1093/infdis/ jir790.
18. Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF. 2005. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350:126-144. http://dx.doi.org/10.1016/j.jmb.2005.04.049. (Pubitemid 40804737)
19. Jafri HS, Wu X, Makari D, Henrickson KJ. 2013. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. Pediatr. Infect. Dis. J. 32:335-340. http://dx.doi.org/10.1097/INF.0b013e318282603a.